Study of PEP02 as a Second Line Therapy for Metastatic Pancreatic Cancer
NCT00813163
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
41
Enrollment
INDUSTRY
Sponsor class
Conditions
Pancreatic Neoplasms
Interventions
DRUG:
PEP02
Sponsor
PharmaEngine